Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

December 29, 2022

Study Completion Date

December 29, 2022

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

Ixabepilone

"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"

DRUG

Bevacizumab

"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."

Trial Locations (2)

21201

Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore

06510

Smilow Cancer Hospital at Yale New Haven, New Haven

All Listed Sponsors
collaborator

R-Pharm US LLC.

INDUSTRY

lead

Yale University

OTHER

NCT03093155 - Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | Biotech Hunter | Biotech Hunter